The most common treatment-related adverse reactions (TRAEs) ≥10% were blood creatine phosphokinase (CPK) increased (20.9%), rash (13.9%), aspartate aminotransferase (AST) increased (12.3%), white blood cell (WBC) count decreased (12.3%), alanine aminotransferase (ALT) increased (11.9%), and pruritus (10.7%); 15 (6.1%) patients had QT prolongation, and there was no ILD reported (36). Here, PIK3C2A is linked to interstitial lung disease.